Examples of using B-cell in English and their translations into Korean
{-}
-
Colloquial
-
Ecclesiastic
-
Ecclesiastic
-
Programming
-
Computer
B-cell.
Leukemia, B-Cell, chronic.
B-Cell Mediated Immunity.
Adaptive immunity: T-cell and B-cell activation and function.
The B-cell duplicates rapidly and starts producing millions of little weapons.
Ibrutinib was developed for additional B-cell malignancies including….
Given the expression of CD20 in B-cell lymphomas, this antigen can serve as a candidate for“targeting” of such lymphomas.
Cells that maintain and control our immune system. They are T-cell, B-cell, NK cell, DC cell and so on.
Bonds between the B-cell receptor and the surface antigen.
Product Description Ibrutinib(USAN, also known as PCI-32765) is an anticancer drug targeting B-cell malignancies.
As B-cells develop and mature, these DNA segments are rearranged in a controlled fashion such that each mature B-cell has a unique rearrangement profile.
Pathologic and clinical features of primary pulmonary extranodal marginal zone B-cell lymphoma of MALT type.
The paper's central question is what allows a population of healthy B-cell progenitors to be replaced over time with a population of cancerous B-cell progenitors?
Since then, he has held positions of increasing responsibility, including Medical Leader and, most recently, Senior Director, Early Development Global Clinical Leader, leading the clinical development of several early-phase compounds for multiple myeloma and various B-cell malignancies.
So we decided that the paradoxical thing that we had created with our B-cell antibodies, our T cells carrier and the HIV Trojan horse should be called"Chimeric Antigen Receptor T cells," or CAR T cells.
ABT-199 is potent and selective inhibitor of B-cell lymphoma-2(BCL-2) family proteins, currently in clinical trials ABT-199 inhibits the growth of BCL-2-dependent tumors in vivo and spares human platelets.
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia(CLL)and indolent B-cell non-Hodgkin lymphoma(NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
This antigen is also expressed on more than 90% of b-cell non Hodgkin's lymphoma(NHL)(Anderson et al. Blood 63(6): 1424-1433(1984)), but is not found on hematopoietic stem cells, Pro-b cells, normal plasma cells or other normal tissues Tedder et al. J. Immunol.
The researchers used data from a clinical trial in which 133 adult patients with relapsed and/or refractory CD19 B-cell ALL, non-Hodgkin lymphoma or chronic lymphocytic leukemia were treated with lymphodepletion chemotherapy followed by infusion of JCAR014, a type of CD19 CAR T-cell therapy developed at Fred Hutchinson Cancer Research Center.
Patients who had neurotoxicity were mostly younger and had B-cell ALL, a higher tumor burden, and more CD19-positive cells in the bone marrow as compared with those who did not develop this side effect.